new-infographic

Protagenic Therapeutics, Inc. has created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

The most advanced of these discoveries is neuropeptide, which plays a key role in regulating depression, anxiety and other stress-related disorders. Novel peptide targets also have applications in the areas of neuroprotection, and neurodegenerative diseases.

A range of indications involving both acute and chronic neurological injury.

We believe that optimal cellular energy metabolism is fundamental to the biology of the brain, and clinical manifestation of aberrant energy metabolism often manifests in debilitating neurological disorders. PT00114’s ability in preclinical models to enhance glucose mobilization and utilization in the brain, maintain energy homeostasis, inhibit stress-related pathways and protect cells from oxidative damage suggests potential therapeutic benefits in a range of indications involving both acute and chronic neurological injury. Potential applications include traumatic brain injury, stroke recovery, and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and ALS, among others.

brain2

A neuropeptide that has been highly-conserved throughout evolution.